Table 1 Clinical characteristics of 15 cases of neonatal Jk^a hemolytic disease

1*

G2P2

39

O Rh+,

Jk a-b+

O Rh+

Jk a + b+

DAT +

Anti-Jk^a 4+,

Platelet antibody+

30.8/0.5 h

219/5d

Y

Y

Y

N

Survival

2 [4]

G2P2

Term

B Rh+, Jk a-

B Rh+, Jk a+

DAT 4+

Anti-Jk^a

NR

350.6/3d

Y

N

N

N

Survival

3 [5]

G2P1

38

A Rh+, Jk a-b+

A RhD+, Jk a + b+

DAT +

Anti-Jk^a

130/14d

263.3/14d

Y

N

N

N

Survival

4 [6]

G1P1

NR

NR

NR

DAT 3+

Anti-Jk^a

75/12d

225.7/4d

Y

N

N

N

Survival

5 [7]

G5P4

NR

A Rh+, Jk a-b+

O Rh+, Jk a + b+

DAT +

Anti-Jk^a

123/4d

335.2/4d

NR

NR

NR

Y

Kernicterus

6 [8]

G2P2

Term

A Rh

Jk a-b+

A RhD+

Jk a + b+

DAT 2+

Anti-Jk^a

Anti-Jk^a(prenatal)

137/2d

308/24 h

NR

NR

N

N

Survival

7 [9]

G2P2

36

A Rh +, Jk a-b+

O RhD+, Jk a + b+

DAT 3+

Anti-Jk^a

122/15 h

222.3/4d

Y

N

Y

N

Survival

8 [10]

G2P2

Term

B Rh+, Jk a-b+

O Rh+, Jk a + b+

DAT +

Anti-Jk^a

144/At birth

69.8//9 h

N

N

N

N

Survival

9 [11]

G7P1

36

A Rh E-

Jk a-b+

A Rh E-

Jk a + b+

DAT 3+

Anti-Jk^a 2+

Anti-E 8+

76/28 h

210/42 h

Y

Y

Y

Y

Survival

10 [12]

G3P3

35

Rhc -, Lan -

Jk a-b+

Rhc+, Lan+

Jk a + b+

DAT +

Anti-Lan, Anti-Jk^a, Anti-c

100/29d

143.6/NR

Y

Y

N

N

Survival

11 [13]

G3P1

35

O Rh+, S-s+,Jk a-

O Rh+, S + s+, Jk a+

DAT +

Anti-Jk^a, Anti-S

83/5w

150.5/6d

NR

Y

N

Y

Survival

12 [14]

G9P2

37

AB Rh E-,

Jk a-b+

A Rh E+

Jk a + b+

DAT 4+

Anti-Jk^a,

Anti-E

92/NR

203.5/NR

Y

N

N

Y

Survival

13 [15]

G1P1

39

B Rh E-e+,Jk a-b+

B E + e+, Jk a + b-

DAT +

Anti-Jk^a, Anti-E

119/6d

289/1d

Y

N

Y

N

Survival

14 [16]

G2P2

39

A Rh E-,

Jk a-

A RhE+

Jk a+

DAT/IAT +

Anti-Jk^a

Anti-E

117/1d

441.2/1d

Y

N

Y

Y

Survival

15 [17]

G3P1

NR

AB Rh C-, Jk a-b+

B Rh C+, Jk a + b+

DAT 3+

Anti-Jk^a, Anti-C

NR

348.8/NR

NR

NR

NR

NR

Death